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Objective: To evaluate the effect of aqueous leaf extract of Cistus ladaniferus
(C. ladaniferus) on glycemic and lipidemic status in diabetic rats.
Methods: Overnight fasted rats were injected intraperitoneally with streptozotocin
(45 mg/kg) to induce experimental diabetes. The aqueous extract of the leaves of
C. ladaniferus was administered orally at the dose of 500 mg/kg body weight to diabetic
rats for a period of 28 days. Hypoglycemic effect, body weight, oral glucose tolerance,
change in lipid parameters, urea, creatinine, aspartate aminotransferase and alanine
aminotransferase levels of diabetic rats treated with aqueous extract were evaluated in
experimental animals.
Results: Administration of 500 mg/kg of C. ladaniferus extract to diabetic rats for 28
days resulted in a signiﬁcant reduction in the levels of blood glucose, alanine amino-
transferase, aspartate aminotransferase, urea and creatinine. Furthermore, the extract of
C. ladaniferus improved glucose tolerance in diabetic rats, and its antidiabetic effect was
similar to the one obtained with glibenclamide. The hypolipidemic effect was demon-
strated by an important decrease in plasma total cholesterol, triglycerides and low density
lipoprotein-cholesterol levels.
Conclusions: It is concluded that C. ladaniferus leaf extract showed an antidiabetic
activity in experimental diabetes which was similar to the one obtained with
glibenclamide.1. Introduction
Diabetes mellitus is a metabolic disease characterized by a
chronic hyperglycemia, resulting from a deﬁciency in insulinproduction by b cells or insulin cellular resistance [1]. The
International Diabetes Federation estimated that 415 million
people worldwide have diabetes in 2015; by 2040, this will
rise to 642 million [2]. Diabetes mellitus is a complicated
metabolic disease which results from the interaction of
multiple factors such as behavioral, genetic predisposition and
environmental risk factors.
In Morocco, many medicinal plants are used for the treatment
of diabetes in folk medicine systems as well as in traditional
healing practices. Furthermore, it is reported that about 1200
plants were used in traditional medicine for the treatment of
diabetes and/or studied for potential antidiabetic activity
worldwide [3]. Scientiﬁc studies on medicinal plants used in folk
medicine to treat diabetes can contribute to the discovery of
novel antidiabetic drugs, which can lead to the development of
alternative therapeutic strategies [3]. In order to control all
pathological complications of diabetes, there is a need of the
development of new alternatives treatments derived from
medicinal plant resources [3].article under the CC BY-NC-ND license (http://
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from the Cistaceae family, originated from the Mediterranean re-
gion, known locally as “Touzal” in the north of Morocco or
“Argale” in other regions of Morocco [4]. This plant is widely used
in traditional medicine in Northern Morocco as antidiarrhoeal and
antispasmodic [5]. Previous studies reported that C. ladaniferus
exerts different pharmacological effects such as antiaggregant
effects [6], antihypertensive [7], antispasmodic [8], antioxidant [9]
and cytotoxic activity against human cancer cells [10]. Essential
oil and various organic extracts of this plant have been shown to
exhibit antifungal and antibacterial effects [11].
According to ethnobotanical data collected in the north of
Morocco, the decoction of C. ladaniferus leaves is traditionally
used in diabetes control and treatment [12]. However, this
ethnobotanical information has never been evaluated
experimentally. Thus, the objective of the present investigation
was to explore the hypoglycemic and hypolipidemic activities
of aqueous leaves extract of C. ladaniferus in diabetic rats.
2. Materials and methods
2.1. Plants material
Fresh leaves of C. ladaniferus (Cistaceae) were collected
from Taounate region (north of Morocco) in March 2015. The
plant material was taxonomically identiﬁed and authenticated
and voucher specimens (No. MA-FSTF 16) were deposited in
the herbarium of the Department of Biology, Faculty of Sciences
and Techniques, Fes, Morocco.
2.2. Preparation of aqueous extract
The leaves of C. ladaniferus were washed with water, air-
dried for 7 days and reduced to a coarse powder. The powder
was extracted by infusion as described in Moroccan folk med-
icine. About 100 g of leaves powder were mixed with 1000 mL
of distilled water for 1 h. The extract was ﬁltered and evaporated
under vacuum at 50 C using a rotary evaporator. The residue
(yield = 26%) was stored at −20 C until use.
2.3. Animals
Healthy adult female andmaleWistar rats weighing 180–230 g
were used in the experiments. Rats were housed in polypropylene
cages at the animal house of the Faculty of Sciences and Tech-
niques (Fes, Morocco). The animals were maintained in standard
environmental conditions and fed standard diet and water ad
libitum. Recommendations of international guidelines were fol-
lowed in animal experiments [13]. All experimental procedures
involving animals were conducted in accordance to the
guidelines on the use and care of experimental animals,
published by the US National Institutes of Health (NIH) and
approved by Institutional Ethical Committee of Sidi Mohamed
Ben Abdellah University, Morocco.
2.4. Acute toxicity
Aqueous leaf extract of C. ladaniferus in 500 mg/kg doses
was administered to the rats orally. All animals were observed
for 24 h after treatment.2.5. Evaluation of antidiabetic activity
2.5.1. Induction of experimental diabetes
To induce experimental diabetes, a single intraperitoneal
dose of 45 mg/kg body weight of streptozotocin (STZ) (Sigma–
Aldrich, St. Louis, MO, USA) was injected to rats after over-
night fasting. STZ was freshly prepared in cold sodium citrate
buffer (0.1 mol/L, pH 4.5). The diabetic state was conﬁrmed by
the measurement of fasted blood glucose in rats after 3 days
following the injection of STZ. Only rats with glycemia higher
than 2 g/L were included in experiments.
2.5.2. Experimental design
The animals were divided into four groups and each group
consisted of six animals. Groups 1 and 2 served as normal and
diabetic control groups, respectively and treated with distilled
water (10mL/kg). Group 3was treated with the aqueous extract of
C. ladaniferus at a dose of 500 mg/kg/day. Group 4 was treated
with 2 mg/kg/day of a standard care drug, glibenclamide. The
500 mg/kg extract dose used in the treatment was chosen from a
preliminary short-term study in our laboratory. Distilled water,
glibenclamide, and plant extract were given orally by gavage as
single daily treatments. The antidiabetic activity ofC. ladaniferus
extract was evaluated in treated animals in comparison to the
control groups, by measuring fasting blood glucose levels and
body weight on Days 1, 7, 14, 21 and 28 of the study.
2.5.3. Oral glucose tolerance test (OGTT)
In order to assess the effect of orally administered
C. ladaniferus extract on systemic glucose homeostasis, an oral
glucose tolerance test was carried out in fasted rats after 4
weeks administration of the extract. In the ﬁnal day of the
experiment, overnight fasted rats were loaded with glucose (2 g/
kg) orally 60 min after the last dose of distilled water, gliben-
clamide or the extract administration. Blood samples were
collected from the tail vein at 0, 30, 60, 90 and 120 min after
glucose loading. Blood glucose levels (g/L) were plotted against
time intervals (min), and the respective areas under the curve
(AUC) were calculated. The AUCs of the curves of each group
were compared and tested for statistical signiﬁcance against the
control diabetic group to evaluate glucose utilization by the
tissues.
2.5.4. Determination of the blood glucose levels
Blood samples were collected from the tip of the tail for
glycemia measurement. In this study, blood glucose concentra-
tions (g/L) were determined at the deﬁned time points, by means
of On Call® Plus glucometer and blood glucose reactive test
strips based on the glucose oxidase method.
2.5.5. Estimation of biochemical parameters
At the end of the 28 days experiment, the animals were
sacriﬁced and blood samples were collected from all the four
groups in tubes containing heparin. Plasma was separated for the
estimation of total cholesterol, low-density lipoprotein-choles-
terol (LDL-C), high-density lipoprotein-cholesterol (HDL-C),
triglycerides, alanine aminotransferase (ALAT), aspartate
aminotransferase (ASAT), urea and creatinine. All biochemical
parameters were studied by an auto-analyzer “Architect C8000”
(Abbott Laboratories, Abbott Park, IL, USA).
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Figure 1. Effect of daily oral administration of the aqueous extract of
C. ladaniferus on blood glucose in STZ-induced diabetic rats.
Values are expressed as mean ± SD, n = 6. a: P < 0.001 compared to normal
control; b: P < 0.01, c: P < 0.001 compared to diabetic control.
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Figure 2. Effect of daily oral administration of the aqueous extract of
C. ladaniferus on blood glucose in STZ-induced diabetic rats during
OGTT.
Values are expressed as mean ± SD, n = 6. a: P < 0.01, b: P < 0.001
compared to diabetic control.
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All data are presented as mean ± SD of the indicated number
of experiments. Results were analyzed by One-way ANOVA
followed by Tukey's multiple comparison post-test performed
using Graph Pad Prism version 6.0 for Windows. Values of P
less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Acute toxicity
After oral administration of the aqueous extracts of leaves of
C. ladaniferus 500 mg/kg doses, no mortality was recorded for
all animals observed 24 h after the leaf extract administration.
3.2. Changes in body weight
Effect of C. ladaniferus extract on body weight is shown in
Table 1. Diabetic control rats showed a progressive fall in body
weight during the study period in comparison to normal control
rats (P< 0.001). The treatment of diabetic rats withC. ladaniferus
extract at a dose of 500 mg/kg for 28 days showed marked
improvement in body weight in comparison to diabetic control
group (P < 0.01). The effect of C. ladaniferus extract on body
weight was comparable to that of glibenclamide.
3.3. Hypoglycemic effect of aqueous extract
The effect of C. ladaniferus extract administration on blood
glucose level is presented in Figure 1. The fasting blood glucose
level (FBG) was measured in all groups of rats on Days 1, 7, 14,
21 and 28 of the treatment. STZ-induced diabetic rats had
signiﬁcantly higher level of FBG compared to that of normal
control rats (P < 0.001). Oral daily administration of
C. ladaniferus extract produced a signiﬁcant decrease in FBG
level, observed from the 7th day after the treatment compared to
diabetic control (P < 0.001). Furthermore, treatment with
C. ladaniferus extract produced 34% fall in FBG level compared
to the FBG level of diabetic control at the end of the experiment.
3.4. Oral glucose tolerance test
Figure 2 presents the changes in blood glucose levels of rats
following the OGTT. Glycemia with a maximum level in normal
and diabetic groups occurred 30 min after the oral glucose
challenge. Administration of C. ladaniferus extract 60 min
before glucose loading produced a signiﬁcant decrease in the
rise in blood glucose level at 30 min (P < 0.001) and 60 min
(P < 0.01) compared to diabetic control. Treatment of diabeticTable 1
Effect of daily oral administration of the aqueous extract of C. ladaniferus o
Treatment
Day 1 Day 7
Group 1 200.00 ± 20.95 197.67 ± 20.53 2
Group 2 207.67 ± 19.76 187.67 ± 26.91 1
Group 3 214.00 ± 11.33 200.33 ± 10.11 1
Group 4 208.17 ± 6.94 202.34 ± 9.04 1
Values are expressed as mean ± SD, n = 6. a: P < 0.01, b: P < 0.001 comparedrats with glibenclamide and C. ladaniferus extract induced a
signiﬁcant reduction in glucose AUC relative to the diabetic
control group by 15% and 12.5%, respectively (Figure 3).
3.5. Changes in lipid proﬁle
Figures 4 and 5 show the levels of plasma total cholesterol
and triglycerides of experimental animals. The plasma levels of
total cholesterol and triglycerides were found to be signiﬁcantly
higher (P < 0.05) in the diabetic control animals in comparisonn body weight in STZ-induced diabetic rats.
Body weight (g)
Day 14 Day 21 Day 28
02.17 ± 21.31 198.00 ± 30.38 200.83 ± 31.28
50.00 ± 17.34a 128.67 ± 23.68b 116.00 ± 21.43b
84.33 ± 9.07d 166.33 ± 6.38c 160.83 ± 5.15d
90.67 ± 7.45d 170.17 ± 5.42c 164.10 ± 5.83d
to normal control; c: P < 0.05, d: P < 0.01 compared to diabetic control.
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Figure 3. Effect of C. ladaniferus extract on total area AUCs of blood
glucose.
Values are expressed as mean ± SD, n = 6. a: P < 0.001 compared to normal
control; b: P < 0.01 compared to diabetic control.
Group 1 Group 2
a
b b
Group 3 Group 4
0.80
0.70
0.60
0.50
0.40
0.30
0.20
0.10
0.00
To
ta
l c
ho
le
ste
ro
l (
g/L
)
Figure 4. Effect of daily oral administration of the aqueous extract of
C. ladaniferus on plasma total cholesterol in STZ-induced diabetic rats.
Values are expressed as mean ± SD, n = 6. a: P < 0.05 compared to normal
control; b: P < 0.05 compared to diabetic control.
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Figure 5. Effect of daily oral administration of the aqueous extract of
C. ladaniferus on plasma triglycerides in STZ-induced diabetic rats.
Values are expressed as mean ± SD, n = 6. a: P < 0.05 compared to normal
control; b: P < 0.05 compared to diabetic control.
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Figure 6. Effect of daily oral administration of the aqueous extract of
C. ladaniferus on plasma LDL-C in STZ-induced diabetic rats.
Values are expressed as mean ± SD, n = 6. a: P < 0.05 compared to normal
control; b: P < 0.05 compared to diabetic control.
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Figure 7. Effect of daily oral administration of the aqueous extract of
C. ladaniferus on plasma HDL-C in STZ-induced diabetic rats.
Values are expressed as mean ± SD, n = 6. a: P < 0.05 compared to normal
control.
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extract showed a signiﬁcant decrease in plasma triglycerides and
total cholesterol when compared with control diabetic rats
(P < 0.05). The leaf extract and glibenclamide showed similar
effects in reducing plasma total cholesterol and triglycerides
levels.
The plasma levels of LDL-C were signiﬁcantly higher in the
diabetic control group than in the normal control group
(Figure 6). Contrariwise, the level HDL-C was signiﬁcantlydiminished in comparison with the normal control group
(P < 0.05). A marked decrease in the level of LDL-C was
observed in diabetic rats treated with glibenclamide without
signiﬁcant change in HDL-C level (Figure 7). The treatment
with C. ladaniferus extract showed a signiﬁcant reduction in
plasma level of LDL-C by 34% (P < 0.05). However, the plasma
level of HDL-C did not show a signiﬁcant increase in compar-
ison with diabetic control rats.3.6. Changes in transaminases, urea and creatinine
levels
Table 2 shows the levels of hepatic and renal markers in
normal and diabetic animals. A signiﬁcant increase in the level
of ASAT and ALAT was observed in diabetic control rats when
compared to non-diabetic control group (P < 0.05). Diabetic rats
treated with C. ladaniferus extract (500 mg/kg body weight) and
glibenclamide showed a signiﬁcant decrease in the levels of
ASAT and ALAT in comparison to control diabetic rats
(P < 0.05). Moreover, a signiﬁcant elevation in urea and
creatinine levels was observed in diabetic control rats when
compared to non-diabetic control group (P < 0.05). Treatment
with C. ladaniferus extract and glibenclamide for 28 days
showed a signiﬁcant reduction in urea and creatinine levels in
the diabetic treated group in comparison with the diabetic un-
treated group (P < 0.05).
Table 2
Effect of daily oral administration of the aqueous extract of C. ladaniferus on levels of urea, creatinine, ALAT and ASAT in STZ-induced diabetic rats.
Treatment Hepatic markers Renal markers
ALAT (IU/L) ASAT (IU/L) Urea (g/L) Creatinine (mg/L)
Group 1 49.67 ± 5.89 110.20 ± 14.53 0.41 ± 0.05 5.51 ± 0.55
Group 2 125.00 ± 18.38b 225.50 ± 25.40c 0.66 ± 0.09b 7.50 ± 1.45b
Group 3 94.17 ± 17.53a 171.50 ± 24.43a 0.54 ± 0.09a 7.02 ± 1.10a
Group 4 87.51 ± 12.50a 171.83 ± 15.21a 0.56 ± 0.07a 6.38 ± 0.86a
Values are expressed as mean ± SD, n = 6. a: P < 0.05 compared to diabetic control; b: P < 0.05, c: P < 0.01 compared to normal control.
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The present data indicated that C. ladaniferus aqueous extract
at the dose of 500 mg/kg signiﬁcantly decreased blood glucose,
triglycerides, total cholesterol, LDL-C, urea, creatinine, ASAT
and ALAT levels. Furthermore, the extract improved glucose
tolerance in treated diabetic rats as compared with control dia-
betic rats. The aqueous extract of C. ladaniferus showed a
comparable antidiabetic effect to glibenclamide, a standard hy-
poglycemic drug which is used as a standard antidiabetic agent
to evaluate the antidiabetic activities in experimental diabetes
studies [14,15].
Severe loss in body weight is one of the characteristics
observed in STZ-induced diabetes, which was observed in the
present study. Administration of C. ladaniferus extract and gli-
benclamide signiﬁcantly improved the body weight loss in
diabetic rats in comparison to diabetic control group. The
observed decrease in body weight of diabetic control rats could
be attributed to insulin deﬁciency, which causes degradation of
structural proteins and lipids that are known to contribute to
body weight [16]. The treatment with C. ladaniferus extract, as
well as glibenclamide enhanced glucose metabolism and thus
improved the body weight in diabetic rats.
TheOGTT evaluates the body's capacity tometabolize glucose.
A marked increase in the AUC of the glucose was observed in
diabetic control rats following the glucose challenge test. This
effect may be due to the reduction of glucose tissue utilization and
an increased hepatic glucose production, as a result of decreased
insulin secretion [17]. The administration of C. ladaniferus extract
showed a marked diminution in the glucose AUC of diabetic rats.
These results revealed thatC. ladaniferus extract increased glucose
utilization which indicates the improvement of glucose
homeostasis in treated diabetic animals.
One of the associated metabolic disorders of diabetes is
dyslipidemia which contributes to secondary complications of
diabetes [18]. Hypercholesterolemia and hypertriglyceridemia
have been reported to occur in diabetic rats [19,20]. Under
normal conditions, the lipolytic hormones action is activated
by insulin allowing hydrolysis of triglycerides and blocks
mobilization of free fatty acids [21]. Contrariwise, in the
diabetic state, the activity of lipoprotein lipase is reduced due
to lack of insulin resulting in hypertriglyceridemia as well as
over production of LDL-C by the liver [22]. The observed
diminution in plasma total cholesterol, triglycerides and LDL-
C status in treated diabetic animals suggests that the extract
possesses insulinotropic effect or insulinomimetic activity.
According to our results, diabetic control rats showed a
signiﬁcant elevation of urea and creatinine levels, which are
used to evaluate renal dysfunction [23]. Administration of
C. ladaniferus extract to diabetic rats signiﬁcantly decreasedthese parameters which could be attributed to the attenuation
of metabolic alterations in protein and nucleic acid
metabolisms which are caused by hyperglycemia in diabetic
states. This ﬁnding was demonstrated in our study by
improved glucose homeostasis in diabetic rats.
Previous studies have reported an increase in ASAT and
ALAT activities in the diabetic state which indicates active liver
damage [24]. Therefore, the increase in the activities of plasma
ASAT and ALAT observed in this study could be attributed to
the hepatocellular damage caused by diabetes. This ﬁnding
was also demonstrated by a previous study reporting a
necrotic liver in diabetic rats [25]. Oral administration of
C. ladaniferus extract and glibenclamide for 28 days to
diabetic groups decreased the activity of these enzymes in
plasma. These results are in agreement with those obtained in
a previous study which reported the antidiabetic effect of
Piper longum root aqueous extract in diabetic rats [26] and
indicate the hepatoprotective effect of C. ladaniferus against
STZ-induced toxicity.
The observed antidiabetic activity of C. ladaniferus may be
attributed to the presence of bioactive compounds such as ﬂa-
vonoids in the extract. The presence of ﬂavonoids in
C. ladaniferus has been reported previously [27,28]. It is
documented that hypoglycemic activities of many medicinal
plants are attributed to the presence of phenolic compounds
and ﬂavonoids [29]. Studies also reported that ﬂavonoids have
antidiabetic properties because they stimulate glucose uptake
in peripheral tissues and attenuate oxidative stress during
diabetic conditions [30,31]. They also exert a stimulatory effect
on insulin secretion by changing Ca2+ concentration [32].
However, the observed antidiabetic activity may be due to
synergistic effect of different classes of bioactive compounds
present in C. ladaniferus extract.
In conclusion, aqueous leaves extract of C. ladaniferus was
effective in decreasing blood glucose levels in STZ-induced
diabetic rats. The hypolipidemic effect was demonstrated by a
signiﬁcant reduction in plasma lipid parameters. The present
results conﬁrm the use of this plant to treat diabetes complica-
tions. Finally, the mechanism of action, as well as the bioactive
compound(s) involved in these pharmacological activities, re-
mains to be determined in addition to toxicological studies.
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